New cancer drug combo enters first human trials

NCT ID NCT04855656

Recruiting now Disease control Sponsor: Debiopharm International SA Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new oral drug called lunresertib, both alone and in combination with two other experimental drugs, for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe dose levels, understand how the drugs work in the body, and look for early signs that they might shrink tumors. The study is enrolling adults and adolescents (12+) with specific genetic changes in their cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

# 1019, UCLA, Westwood Cancer Center
COMPLETED

Los Angeles, California, 90095, United States
#1001, The University of Texas M.D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
#1002, Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
#1004, Memorial Sloan Kettering Cancer Institute
RECRUITING

New York, New York, 10065, United States
#1007, Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
#1008, Columbia University
ACTIVE_NOT_RECRUITING

New York, New York, 10032, United States
#1010, University of Pennsylvania
COMPLETED

Philadelphia, Pennsylvania, 19104, United States
#1011, Washington University
RECRUITING

St Louis, Missouri, 63130, United States
#1012, Yale
RECRUITING

New Haven, Connecticut, 06520, United States
#1013, The University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
#1016, Mayo Clinic
RECRUITING

Rochester, Minnesota, 55902, United States
#1017, Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
#1023, START Midwest
RECRUITING

Grand Rapids, Michigan, 49503, United States
#1025, University of California San Francisco
RECRUITING

San Francisco, California, 94158, United States
#1027, University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States
#1030, Women & Infants Hospital of Rhode Island
RECRUITING

Providence, Rhode Island, 02903, United States
#1032, Northwell Health Cancer Institute
RECRUITING

New Hyde Park, New York, 11042, United States
#2001, Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2C1, Canada
#2002, The Hospital for Sick Children
COMPLETED

Toronto, Ontario, M5G 1X8, Canada
#2003, The Research Institute of the McGill University Health Centre
COMPLETED

Montreal, Quebec, H4A 3J1, Canada
#3003, Sarah Cannon Research Institute
RECRUITING

London, W1G 6AD, United Kingdom
#4001, Rigshospitalet - Blegdamsvej
RECRUITING

Copenhagen, Denmark

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR